Unum Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Unum
Therapeutics Inc., a clinical stage biopharmaceutical company
developing a universal cellular immunotherapy to treat multiple
cancers, today announced that President and Chief Executive Officer Chuck
Wilson will present at the Wedbush PacGrow Healthcare
Conference on August 17, 2016 at 1:20 pm ET. The conference is being
held August 16-17, 2016 at the Le Parker Meridien in New York.

Unum Therapeutics

Unum uses proprietary T-cell engineering technology in combination with
tumor-targeting antibodies to activate the body’s own immune system to
fight cancer. The Company’s lead program, which combines Unum’s
proprietary Antibody-Coupled T-cell Receptor (ACTR) technology with
rituximab, is in Phase 1 clinical testing to assess its safety and
efficacy. The company is headquartered in Cambridge, MA. For more
information, visit www.unumrx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160808005255/en/